Evopoint Biosciences Secures $97M in Series E Round Led by Tencent and Guoxin for Medical Breakthroughs
Evopoint Biosciences Secures $97M in Series E Round Led by Tencent and Guoxin for Medical Breakthroughs
02/21/24, 11:13 AM
Location
suzhouMoney raised
$97.4 million
Industry
biotechnology
Round Type
series e
Investors
Gic, Cicc Capital, Oceanpine Capital, Guoxin Investment, Tencent Investment
Evopoint Biosciences has secured a Series E funding round of 700 million yuan ($97.4 million), spearheaded by Tencent Investment and Guoxin Investment, to propel the company's ambitious clinical trials to new heights.
Company Info
Location
suzhou, jiangsu, china
Additional Info
Since its inception in 2017, Evopoint Biosciences has been at the forefront of medical innovation. With a robust pipeline of nine clinical candidates, including two in the critical Phase III of clinical development, the company has consistently pushed the boundaries of medical science. Specializing in oncology, anti-infectives, and metabolic diseases, Evopoint's research and development efforts have not only garnered attention but have also set the stage for potential groundbreaking treatments that could change the course of modern medicine.